A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas

In order to achieve higher dosages than previously used in clinical trials, we conducted a phase I trial to determine the maximum tolerated dose (MTD) for the combination of erlotinib and sirolimus for the treatments of recurrent malignant gliomas. Patients with pathologically proven World Health Or...

Descripción completa

Detalles Bibliográficos
Autores principales: Nghiemphu, Phioanh Leia, Lai, Albert, Green, Richard M., Reardon, David A., Cloughesy, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472078/
https://www.ncbi.nlm.nih.gov/pubmed/22918789
http://dx.doi.org/10.1007/s11060-012-0960-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472078/
https://www.ncbi.nlm.nih.gov/pubmed/22918789
http://dx.doi.org/10.1007/s11060-012-0960-y

Ejemplares similares